US4555524A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods
Assignee: Dolorgiet GmbH and Co KG
•
Filing: 1982-11-23
•
Granted: 1985-11-26
•
Expires: 2002-11-23
Abstract
Abstract An externally administrable pharmaceutical which contains an effective amount of 2-(4-isobutylphenyl)propionic acid in a base is obtained by drug dissolution in a mixture of C 6-12 carboxylic acid triglycerides, glycerol monostearate-polyoxyethylene stearate mixture and polyoxyethylene-fatty acid esters. A cream is obtained by stirring this solution with an aqueous phase in the presence of heat.
Inventors
- 👤 Klaus Gruber
- 👤 Manfred Lohner
- 👤 Klaus Posselt
- 👤 Hans H. Wagener
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:15
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/185; A61K31/19; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/10; A61K9/127; A61K9/1274; A61P; A61P29/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
83 words
A transdermal medicament for the delivery of 2-(4-isobutylphenyl)-propionic acid to a patient which comprises a sustained release vehicle containing a pharmaceutically effective amount of 2-(4-isobutylphenyl)-propionic acid, said sustained release vehicle comprising a base capable of substantially dissolving all of said 2-(4-isobutylphenyl)-propionic acid and containing from about 30 to about 50 parts by weight C 6-12 carboxylic acid triglyceride, about 4 to about 10 parts by weight glycerol monostearate-polyoxyethylene stearate mixture and about 2 to about 10 parts by weight polyoxyethylene fatty acid ester.
Claim 2
Dependent Claim
83 words
A transdermal medicament for the delivery of 2-(4-isobutylphenyl)-propionic acid to a patient which comprises a sustained release vehicle containing a pharmaceutically effective amount of 2-(4-isobutylphenyl)-propionic acid, said sustained release vehicle comprising a base capable of substantially dissolving all of said 2-(4-isobutylphenyl)-propionic acid and containing from about 30 to about 50 parts by weight C 6-12 carboxylic acid triglyceride, about 4 to about 10 parts by weight glycerol monostearate-polyoxyethylene stearate mixture and about 2 to about 10 parts by weight polyoxyethylene fatty acid ester.
Claim 3
Dependent Claim
76 words
A transdermal medicament cream for the delivery of 2-(4-isobutylphenyl)-propionic acid to a patient which comprises in intimate mixture an aqueous phase mixed with a base containing a pharmaceutically effective amount of 2-(4-isobutylphenyl)-propionic acid in admixture with from about 30 to about 50 parts by weight C 6-12 carboxylic acid triglyceride, about 4 to about 10 parts by weight glycerol monostearate-polyoxyethylene stearate mixture and from about 2 to about 10 parts by weight polyoxyethylene fatty acid ester.
Claim 4
Dependent Claim
76 words
A transdermal medicament cream for the delivery of 2-(4-isobutylphenyl)-propionic acid to a patient which comprises in intimate mixture an aqueous phase mixed with a base containing a pharmaceutically effective amount of 2-(4-isobutylphenyl)-propionic acid in admixture with from about 30 to about 50 parts by weight C 6-12 carboxylic acid triglyceride, about 4 to about 10 parts by weight glycerol monostearate-polyoxyethylene stearate mixture and from about 2 to about 10 parts by weight polyoxyethylene fatty acid ester.
Claim 5
Dependent Claim
45 words
A transdermal medicament of claim 2 wherein said aqueous phase comprises from about 2 to about 10 parts by weight, 1,2-propanediol, about 0.1 to about 1 part by weight 4-hydroxybenzoic acid methyl ester, and from about 0.1 to about 1 part by weight xanthan gum.
Claim 6
Dependent Claim
32 words
A method of topically providing an analgesic effect to a patient suffering from a localized pain which comprises topically administering to said patient the transdermal medicament of claim 1, 2 or 3.
Claim 7
Dependent Claim
30 words
A method of topically providing an antirheumatic effect to a patient suffering from rheumatism, which comprises topically administering to said patient the transdermal medicament of claim 1, 2 or 3.
Claim 8
Dependent Claim
60 words
A method of systemically administering 2-(4-isobutylphenyl)-propionic acid to a patient without a first-pass effect which comprises transdermally administering 2-(4-isobutylphenyl)-propionic acid contained in the transdermal medication of claim 1, 2 or 3, whereby a systemic effect of 2-(4-isobutylphenyl)-propionic acid is delivered to said patient without passage of 2-(4-isobutylphenyl)-propionic acid through the liver of said patient prior to delivery to the bloodstream.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-11-25 | 1989-05-27 | 1989-11-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-11-25 | 1993-05-27 | 1993-11-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-11-25 | 1997-05-27 | 1997-11-26 | $7700.00 | Window Closed / Lapsed |